Date:		3/3/2024			
Your Name:		Nancy Alnassar			
Manuscript Title:		_	Differential Expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas		
Maı	nuscript Number (if kr	nown):	TLCR-24-28-CL		
content of your manuscript. "Rela affected by the content of the ma indicate a bias. If you are in doub		pt. "Rela f the man in doubt	e ask you to disclose all relationships/activities/interests listed below that are related to the ated" means any relation with for-profit or not-for-profit third parties whose interests may be nuscript. Disclosure represents a commitment to transparency and does not necessarily t about whether to list a relationship/activity/interest, it is preferable that you do so. es/interests should be defined broadly. For example, if your manuscript pertains to the		
epic	demiology of hyperten	nsion, you	ı should declare all	-	facturers of antihypertensive medication, even if
In item #1 below, report all suppo frame for disclosure is the past 36		all suppor	t for the work repo	orted in this manuscript v	vithout time limit. For all other items, the time
		Nama all	entities with who	m you have this	Specifications/Comments (e.g., if payments were
		ivaille all	entities with who	ili you liave tilis	specifications/comments (e.g., it payments were
		relations	hip or indicate noi	ne (add rows as needed)	made to you or to your institution)
	1	relations	•	ne (add rows as needed) : Since the initial planning	
1	All support for the	relations	Time frame	•	
1	All support for the present manuscript (e.g.,	[□] N o	Time frame one ity of Portsmouth U	•	
1	All support for the present	∏ No	Time frame one ity of Portsmouth U	Since the initial planning	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing,	[□] N o	Time frame one ity of Portsmouth U	Since the initial planning	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	[□] N o	Time frame one ity of Portsmouth U	Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing	[□] N o	Time frame one ity of Portsmouth U	Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for	[□] N o	Time frame one ity of Portsmouth U ship.	Since the initial planning	cof the work Click the tab key to add additional rows.
2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item	[□] No [Universi	Time frame one ity of Portsmouth U ship.	: Since the initial planning	cof the work Click the tab key to add additional rows.
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not	[□] No [Universi	Time frame one ity of Portsmouth Uship.	: Since the initial planning	cof the work Click the tab key to add additional rows.

1 12/13/2021 ICMJE Disclosure Form

licenses

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	[⊠] None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None			
13	Other financial or non-financial interests	⊠ None			
Plea	Please place an "X" next to the following statement to indicate your agreement:				

3 12/13/2021 ICMJE Disclosure Form

Date:	2/26/2024
Your Name:	[Jonathan Derry]
Manuscript Title:	[Differential Expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas.]
Manuscript Number (if known):	TLCR-24-28-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None Time frame: past 36 month	Click the tab key to add additional rows.
2	Grants or contracts from any entity (if not indicated in item #1 above).	[⊠] None	
3	Royalties or licenses	None Non	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	DEM Biopharma Inc Solu Therapeutics Keros Therapeutics	Provide consulting services Provide consulting services Provide consulting services
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	[⊠] None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	□ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	Presage Biosciences	I have a 0.25 FTE position with Presage	
Plea [⊠]	Please place an "X" next to the following statement to indicate your agreement: I certify that I have answered every question and have not altered the wording of any of the questions on this form.			

Date:	2/26/2024
Your Name:	Giuseppe Luigi Banna
Manuscript Title:	Differential Expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas.
Manuscript Number (if known):	TLCR-24-28-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		e all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial planning	of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	Click the tab key to add additional rows.
		Time frame: past 36 month	S
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	AstraZeneca, Amgen	
0	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Astellas, Astrazeneca, Amgen, Bayer	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	Merck, Janssen	
8	Patents planned, issued or pending	□ None 4 patents with ST Microelectronics	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
11	Stock or stock options	None			
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None			
13	Other financial or non-financial interests	None			
Plea	Please place an "X" next to the following statement to indicate your agreement:				

Gunga Luri Brune

3

Date: Your Name: Manuscript Title:			2/26/2024 Dariusz C. Gorecki Differential Expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas.		
Mar	nuscript Number (if k	known)	: TLCR-24-28-CL		
con [.] affe	tent of your manuscr cted by the content o	ript. "R of the r	we ask you to disclose all relationships/activitie elated" means any relation with for-profit or no nanuscript. Disclosure represents a commitmenable about whether to list a relationship/activity	ot-for-profit third parties whose interests may be nt to transparency and does not necessarily	
epic	demiology of hyperte	nsion,	ities/interests should be defined broadly. For eyou should declare all relationships with manufed in the manuscript.	example, if your manuscript pertains to the acturers of antihypertensive medication, even if	
	em #1 below, report ne for disclosure is th		port for the work reported in this manuscript w 36 months.	vithout time limit. For all other items, the time	
			all entities with whom you have this onship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.		None	Click the tab key to add additional rows.	
			Time frame: past 36 month	ns	
2	Grants or contracts from any entity (if not indicated in item #1 above).		None		
3	Royalties or licenses		None		

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	None None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	[⊠] None	
7	Support for attending meetings and/or travel	[⊠] None	
8	Patents planned, issued or pending	⊠ None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	[⊠] None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
11	Stock or stock options	[⊠] None		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	[⊠] None		
13	Other financial or non-financial interests	⊠ None		
Please place an "X" next to the following statement to indicate your agreement:				

3 12/13/2021 ICMJE Disclosure Form